IQN path ASBL report from the first European cfDNA consensus meeting

expert opinion on the minimal requirements for clinical ctDNA testing

Zandra C. Deans, Rachel Butler, Melanie Cheetham, Elisabeth M.C. Dequeker, Jennifer A. Fairley, Francesca Fenizia, Jacqueline A. Hall, Cleo Keppens, Nicola Normanno, Ed Schuuring, Simon J. Patton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy testing. Representatives of those participating laboratories were invited to attend a workshop to discuss the findings and how to achieve quality implementation of cfDNA testing in the clinical setting, the discussion and outcomes of this consensus meeting are described below. Predictive molecular profiling using tumour tissue in order to select cancer patients eligible for targeted therapy is now routine in diagnostic pathology. If insufficient tumour tissue material is available, in some circumstances, recent European Medicines Agency (EMA) guidance recommends mutation testing with plasma cfDNA. Clinical applications of cfDNA include treatment selection based on clinically relevant mutations derived from pre-treatment samples and the detection of resistant mutations upon progression of the disease. In order to identify tumour-related mutations in amongst other nucleic acid material found in plasma samples, highly sensitive laboratory methods are needed. In the workshop, we discussed the variable approaches taken with regard to cfDNA extraction methods, the tests, and considered the impact of false-negative test results. We explored the lack of standardisation of complex testing procedures ranging from plasma collection, transport, processing and storage, cfDNA extraction, and mutation analysis, to interpretation and reporting of results. We will also address the current status of clinical validation and clinical utility, and its use in current diagnosis. This workshop revealed a need for guidelines on with standardised procedures for clinical cfDNA testing and reporting, and a requirement for cfDNA-based external quality assessment programs.

Original languageEnglish
JournalVirchows Archiv
DOIs
Publication statusPublished - 2019

Fingerprint

Expert Testimony
DNA
Mutation
Neoplasms
Education
Biopsy
Nucleic Acids
Disease Progression
Therapeutics
Guidelines
Pathology

Keywords

  • cfDNA
  • ctDNA
  • Liquid biopsy testing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

IQN path ASBL report from the first European cfDNA consensus meeting : expert opinion on the minimal requirements for clinical ctDNA testing. / Deans, Zandra C.; Butler, Rachel; Cheetham, Melanie; Dequeker, Elisabeth M.C.; Fairley, Jennifer A.; Fenizia, Francesca; Hall, Jacqueline A.; Keppens, Cleo; Normanno, Nicola; Schuuring, Ed; Patton, Simon J.

In: Virchows Archiv, 2019.

Research output: Contribution to journalArticle

Deans, Zandra C. ; Butler, Rachel ; Cheetham, Melanie ; Dequeker, Elisabeth M.C. ; Fairley, Jennifer A. ; Fenizia, Francesca ; Hall, Jacqueline A. ; Keppens, Cleo ; Normanno, Nicola ; Schuuring, Ed ; Patton, Simon J. / IQN path ASBL report from the first European cfDNA consensus meeting : expert opinion on the minimal requirements for clinical ctDNA testing. In: Virchows Archiv. 2019.
@article{a979c95101a04e809b7ef984a4375356,
title = "IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing",
abstract = "Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy testing. Representatives of those participating laboratories were invited to attend a workshop to discuss the findings and how to achieve quality implementation of cfDNA testing in the clinical setting, the discussion and outcomes of this consensus meeting are described below. Predictive molecular profiling using tumour tissue in order to select cancer patients eligible for targeted therapy is now routine in diagnostic pathology. If insufficient tumour tissue material is available, in some circumstances, recent European Medicines Agency (EMA) guidance recommends mutation testing with plasma cfDNA. Clinical applications of cfDNA include treatment selection based on clinically relevant mutations derived from pre-treatment samples and the detection of resistant mutations upon progression of the disease. In order to identify tumour-related mutations in amongst other nucleic acid material found in plasma samples, highly sensitive laboratory methods are needed. In the workshop, we discussed the variable approaches taken with regard to cfDNA extraction methods, the tests, and considered the impact of false-negative test results. We explored the lack of standardisation of complex testing procedures ranging from plasma collection, transport, processing and storage, cfDNA extraction, and mutation analysis, to interpretation and reporting of results. We will also address the current status of clinical validation and clinical utility, and its use in current diagnosis. This workshop revealed a need for guidelines on with standardised procedures for clinical cfDNA testing and reporting, and a requirement for cfDNA-based external quality assessment programs.",
keywords = "cfDNA, ctDNA, Liquid biopsy testing",
author = "Deans, {Zandra C.} and Rachel Butler and Melanie Cheetham and Dequeker, {Elisabeth M.C.} and Fairley, {Jennifer A.} and Francesca Fenizia and Hall, {Jacqueline A.} and Cleo Keppens and Nicola Normanno and Ed Schuuring and Patton, {Simon J.}",
year = "2019",
doi = "10.1007/s00428-019-02571-3",
language = "English",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - IQN path ASBL report from the first European cfDNA consensus meeting

T2 - expert opinion on the minimal requirements for clinical ctDNA testing

AU - Deans, Zandra C.

AU - Butler, Rachel

AU - Cheetham, Melanie

AU - Dequeker, Elisabeth M.C.

AU - Fairley, Jennifer A.

AU - Fenizia, Francesca

AU - Hall, Jacqueline A.

AU - Keppens, Cleo

AU - Normanno, Nicola

AU - Schuuring, Ed

AU - Patton, Simon J.

PY - 2019

Y1 - 2019

N2 - Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy testing. Representatives of those participating laboratories were invited to attend a workshop to discuss the findings and how to achieve quality implementation of cfDNA testing in the clinical setting, the discussion and outcomes of this consensus meeting are described below. Predictive molecular profiling using tumour tissue in order to select cancer patients eligible for targeted therapy is now routine in diagnostic pathology. If insufficient tumour tissue material is available, in some circumstances, recent European Medicines Agency (EMA) guidance recommends mutation testing with plasma cfDNA. Clinical applications of cfDNA include treatment selection based on clinically relevant mutations derived from pre-treatment samples and the detection of resistant mutations upon progression of the disease. In order to identify tumour-related mutations in amongst other nucleic acid material found in plasma samples, highly sensitive laboratory methods are needed. In the workshop, we discussed the variable approaches taken with regard to cfDNA extraction methods, the tests, and considered the impact of false-negative test results. We explored the lack of standardisation of complex testing procedures ranging from plasma collection, transport, processing and storage, cfDNA extraction, and mutation analysis, to interpretation and reporting of results. We will also address the current status of clinical validation and clinical utility, and its use in current diagnosis. This workshop revealed a need for guidelines on with standardised procedures for clinical cfDNA testing and reporting, and a requirement for cfDNA-based external quality assessment programs.

AB - Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy testing. Representatives of those participating laboratories were invited to attend a workshop to discuss the findings and how to achieve quality implementation of cfDNA testing in the clinical setting, the discussion and outcomes of this consensus meeting are described below. Predictive molecular profiling using tumour tissue in order to select cancer patients eligible for targeted therapy is now routine in diagnostic pathology. If insufficient tumour tissue material is available, in some circumstances, recent European Medicines Agency (EMA) guidance recommends mutation testing with plasma cfDNA. Clinical applications of cfDNA include treatment selection based on clinically relevant mutations derived from pre-treatment samples and the detection of resistant mutations upon progression of the disease. In order to identify tumour-related mutations in amongst other nucleic acid material found in plasma samples, highly sensitive laboratory methods are needed. In the workshop, we discussed the variable approaches taken with regard to cfDNA extraction methods, the tests, and considered the impact of false-negative test results. We explored the lack of standardisation of complex testing procedures ranging from plasma collection, transport, processing and storage, cfDNA extraction, and mutation analysis, to interpretation and reporting of results. We will also address the current status of clinical validation and clinical utility, and its use in current diagnosis. This workshop revealed a need for guidelines on with standardised procedures for clinical cfDNA testing and reporting, and a requirement for cfDNA-based external quality assessment programs.

KW - cfDNA

KW - ctDNA

KW - Liquid biopsy testing

UR - http://www.scopus.com/inward/record.url?scp=85065169022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065169022&partnerID=8YFLogxK

U2 - 10.1007/s00428-019-02571-3

DO - 10.1007/s00428-019-02571-3

M3 - Article

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

ER -